Search

Your search keyword '"OVERALL survival"' showing total 520 results

Search Constraints

Start Over You searched for: Descriptor "OVERALL survival" Remove constraint Descriptor: "OVERALL survival" Topic breast cancer prognosis Remove constraint Topic: breast cancer prognosis Publication Year Range Last 50 years Remove constraint Publication Year Range: Last 50 years Publication Type Periodicals Remove constraint Publication Type: Periodicals
520 results on '"OVERALL survival"'

Search Results

1. Omission of Completion Axillary Lymph Node Dissection for Patients with Breast Cancer Treated by Upfront Mastectomy and Sentinel Node Isolated Tumor Cells or Micrometastases.

2. Depicting Biomarkers for HER2-Inhibitor Resistance: Implication for Therapy in HER2-Positive Breast Cancer.

3. Clinical and Genomic Risk for Late Breast Cancer Recurrence and Survival.

4. Insights into the performance of PREDICT tool in a large Mainland Chinese breast cancer cohort: a comparative analysis of versions 3.0 and 2.2.

5. The Prognostic Impact of HER2-Low and Menopausal Status in Triple-Negative Breast Cancer.

6. Somatic Mutations in KEAP1-NRF2 Complex in Breast Cancer.

7. Neoadjuvant Chemotherapy in Breast Cancer: Evaluation of the Impact on Surgical Outcomes and Prognosis.

8. The role of surgery in stage IV breast cancer: Clinical experiences of 62 patients.

9. Quantifying spatial CXCL9 distribution with image analysis predicts improved prognosis of triple-negative breast cancer.

10. Palliative Care Use Trends, Racial/Ethnic Disparities, and Overall Survival Differences Among Patients With Metastatic Breast Cancer.

11. Treatment Outcomes of Stereotactic Ablative Body Radiotherapy on Extra-cranial Oligometastatic and Oligoprogressive Breast Cancer: Mature Results from a Single Institution Experience.

12. Management and Clinical Outcomes of Breast Cancer in Women Diagnosed with Hereditary Cancer Syndromes in a Clinic-Based Sample from Colombia.

13. Deep multi-modal fusion network with gated unit for breast cancer survival prediction.

14. Overall Survival and Prognostic Factors in Metastatic Triple-Negative Breast Cancer: A National Cancer Database Analysis.

15. The Impact of the Coexpression of MET and ESR Genes on Prognosticators and Clinical Outcomes of Breast Cancer: An Analysis for the METABRIC Dataset.

16. Real-World Experience among Elderly Metastatic Breast Cancer Patients Treated with CDK4/6 Inhibitor-Based Therapy.

17. Two Hematological Markers Predicting the Efficacy and Prognosis of Neoadjuvant Chemotherapy Using Lobaplatin Against Triple-Negative Breast Cancer.

18. Early Stage Breast Cancer: Does Histologic Subtype (Ductal vs. Lobular) Impact 5 Year Overall Survival?

19. EMP2 Serves as a Functional Biomarker for Chemotherapy-Resistant Triple-Negative Breast Cancer.

20. Triple-Negative Breast Cancer Treatment Advancements: A Review of Evolving Strategies.

21. Prognostic Importance of PD-L1 Expression in Breast Carcinomas.

22. Adherence Rate to Alliance for Clinical Trials in Oncology Z0011 Trial Based on Breast Cancer Subtype.

23. Cyclin-dependent kinase 4/6 inhibitors in the treatment of advanced or metastatic breast cancer.

24. Metastatic Breast Cancer: Prolonging Life in Routine Oncology Care.

25. A comprehensive analysis of the prognostic characteristics of microRNAs in breast cancer.

26. Systematic Review of Survival Outcomes of Pregnancy-Associated Breast Cancer in Asian Countries.

27. A Preliminary Evaluation of Advanced Oxidation Protein Products (AOPPs) as a Potential Approach to Evaluating Prognosis in Early-Stage Breast Cancer Patients and Its Implication in Tumour Angiogenesis: A 7-Year Single-Centre Study.

28. HER2-Low Status Was Associated With Better Breast Cancer-Specific Survival in Early-Stage Triple-Negative Breast Cancer.

29. GNPNAT1 is a Biomarker That Predicts a Poor Prognosis of Breast Cancer.

30. Breast Cancer in Young Women: Is It Different? A Single-Center Retrospective Cohort Study.

31. Subtype-Specific Survival of Young Women with Breast Cancer and Its Interaction with the Germline BRCA Status.

32. High Numbers of CD163+ Tumor-Associated Macrophages Predict Poor Prognosis in HER2+ Breast Cancer.

33. Treatment Patterns and Health Outcomes among Patients with HER2 IHC0/-Low Metastatic or Recurrent Breast Cancer.

34. The Emerging Role of Tertiary Lymphoid Structures in Breast Cancer: A Narrative Review.

35. Predictive Value of Metabolic Parameters in Pretreatment 18F-FDG PET/CT with Regard to Molecular Subtype, Immunohistochemistry, and Overall Survival in Primary Invasive Ductal Breast Cancer.

36. Long-Term Outcomes and Predictors of Response in Breast Cancer Patients with Advanced Nodal Involvement.

37. Stereotactic Radiosurgery for Women Older than 65 with Breast Cancer Brain Metastases.

38. Impact of Primary Breast Surgery on Overall Survival of Patients With De Novo Metastatic Breast Cancer: A Systematic Review and Meta-Analysis.

39. Cholesterol-modified prognostic nutritional index (CPNI) as an effective tool for assessing the nutrition status and predicting survival in patients with breast cancer.

40. Quantitative Assessment of Ribociclib Exposure–Response Relationship to Justify Dose Regimen in Patients with Advanced Breast Cancer.

41. Comparing Prognosis for BRCA1 , BRCA2 , and Non-BRCA Breast Cancer.

42. Outcomes in Premenopausal Patients with HR+/HER2− Breast Cancer and Lymph Node Micrometastasis Based on the 21-Gene Recurrence Score.

43. The Clinicopathological Features and Prognostic Significance of HER2-Low in Early Breast Tumors Patients Prognostic Comparison of HER-Low and HER2-Negative Breast Cancer Stratified by Hormone Receptor Status.

44. An Innovative Non-Linear Prediction Model for Clinical Benefit in Women with Newly Diagnosed Breast Cancer Using Baseline FDG-PET/CT and Clinical Data.

45. Assessing the relationship between tumor proliferation and prognosis in breast cancer patients: A pathological analysis.

46. Potential Role of Zinc Finger 365 rs10822013 and rs10995190 in Mammographic Density, Sporadic Breast Cancer Risk, and Prognosis.

47. Ten-Year Outcomes of Stereotactic Body Radiotherapy for Oligometastatic Breast Cancer: Does Synchronous Oligometastatic Breast Cancer Benefit?

48. Treating brain metastases in metastatic breast cancer: outcomes after stereotactic radiosurgery examined in a retrospective, single-center cohort analysis.

49. Twenty-Year Follow-Up of a Phase II Trial of Taxotere/Carboplatin/Herceptin in Patients With Metastatic HER2-Positive Breast Cancer.

50. Efficacy and safety of cyclin‐dependent kinase 4/6 inhibitor in patients with advanced breast cancer: A real‐world experience.

Catalog

Books, media, physical & digital resources